Terns Pharmaceuticals Inc. (TERN)
$52.95
$52.15
(6,518.75%)
As on 15-May-2026 16:00EDT
Market cap
$6,117 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
6.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-5.8
-
Debt to Equity
0
-
Book Value
$10.8
-
EPS
$-1
-
Face value
--
-
Shares outstanding
115,521,157
6 Years Aggregate
CFO
$-272.77 Mln
EBITDA
$-337.05 Mln
Net Profit
$-327.81 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Terns Pharmaceuticals (TERN)
| 31.1 | 0.5 | 40.1 | 1,804.7 | 61.1 | 27.2 | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Terns Pharmaceuticals (TERN)
| 629.2 | -14.5 | -36.2 | 44.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Terns Pharmaceuticals (TERN)
|
53.0 | 6,116.9 | 0.0 | -96.2 | -- | -14.2 | -- | 6.1 |
| 115.1 | 6,732.3 | 22.3 | -228.9 | -918.3 | -53.4 | -- | 16.7 | |
| 24.5 | 1,728.3 | 0.0 | -235.1 | -- | -91 | -- | 163.8 | |
| 0.3 | 251.2 | 5.2 | 12.0 | -156.5 | 162.5 | 137.5 | 0.0 |
Shareholding Pattern
View DetailsAbout Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that... is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC. Read more
-
President & Head of Research & Development
Dr. Erin Quirk M.D.
-
President & Head of Research & Development
Dr. Erin Quirk M.D.
-
Headquarters
Foster City, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Terns Pharmaceuticals (TERN)
What is the current share price of Terns Pharmaceuticals Inc (TERN) Today?
The share price of Terns Pharmaceuticals Inc (TERN) is $52.95 (NASDAQ) as of 15-May-2026 16:00 EDT. Terns Pharmaceuticals Inc (TERN) has given a return of 61.12% in the last 3 years.
What is the current PB & PE ratio of Terns Pharmaceuticals Inc (TERN)?
Since, TTM earnings of Terns Pharmaceuticals Inc (TERN) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-39.12 |
3.74 |
2024 |
-5.69 |
1.46 |
2023 |
-5.20 |
1.84 |
2022 |
-9.23 |
2.01 |
2021 |
-3.56 |
1.11 |
What is the 52 Week High and Low of Terns Pharmaceuticals Inc (TERN)?
The 52-week high and low of Terns Pharmaceuticals Inc (TERN) are Rs 53.19 and Rs 0.49 as of 30-Aug-2026.
What is the market cap of Terns Pharmaceuticals Inc (TERN)?
Terns Pharmaceuticals Inc (TERN) has a market capitalisation of $ 6,117 Mln as on 15-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Terns Pharmaceuticals Inc (TERN)?
Before investing in Terns Pharmaceuticals Inc (TERN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.